摘要抗髓鞘少突胶质细胞糖蛋白（MOG）-IgG虽然是抗MOG抗体相关疾病（MOGAD）诊断的生物学标志物，但MOG-IgG本身在疾病诊断的特异性仍然存在一些争议。临床上，MOG-IgG低滴度MOGAD患者临床异质性显著，低滴度的MOG-IgG甚至可以在无症状人群中被检测到。同时，MOG-IgG阳性者常合并多种其他神经系统自身免疫抗体阳性。因此，MOG-IgG与MOGAD的关系错综复杂，MOGAD的发病机制可能存在MOG-IgG以外的免疫因素参与。文中综述合并其他神经免疫抗体的MOGAD的研究进展，为将来临床医师对这类疾病的早期识别和治疗提供帮助。

abstractsAlthough myelin oligodendrocyte glycoprotein (MOG)-IgG is a biological marker for diagnosing MOG antibody-associated disease (MOGAD), the specificity of MOG-IgG in disease diagnosis remains controversial. In clinical practice, there is significant heterogeneity in MOGAD patients with low titer of MOG-IgG and low titer MOG-IgG can even be detected in asymptomatic populations. At the same time, MOG-IgG-positive individuals often combine with the positivity of other multiple autoimmune antibodies in the nervous system. Therefore, the relationship between MOG-IgG and MOGAD is complex, and the pathogenesis of MOGAD may involve immune factors other than MOG-IgG. This article reviews the research progress of MOGAD combined with other neuroimmune antibodies, assisting in the early identification and treatment of such diseases by clinical physicians in the future.